Williams, W. R. (2025) Nucleotide Relative Molecular Similarity within Anti-Psychotic Drug Structures. Journal of Biosciences and Medicines, 13, 106-117. doi: 10.4236/jbm.2025.136010 .

RVPH Open Label Extension Key Opinion Leader Event Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) held a key opinion ...

It was the first new mechanism-of-action approved for schizophrenia ... work in combination with a generic antipsychotic to provide more relief than one drug alone.

Understanding a drug’s mechanism of action (MOA) can greatly increase the likelihood of successful clinical trials by identifying biomarkers of patient response and providing a rationale for ...

are drugs that target certain neurotransmitters to manage the symptoms of mental health conditions. Antipsychotics are classified into two groups depending on their “mechanism of action,” or ...

Xanomeline-trospium provides a "new mechanism of action, a new system that's being targeted in the treatment of schizophrenia, and the effect size was rather large, so the drug didn't just squeak ...

Researchers at the Icahn School of Medicine at Mount Sinai have uncovered insights into the potential mechanism of action of the antipsychotic medication ... pave the way for the development of ...

In this follow-up, I’ll take a look at two new antipsychotic medications—ulotaront and xanomeline/trospium—that seem to have genuinely novel mechanisms of action and try to answer whether ...

And while he doesn’t pretend to fully understand antipsychotics either ... would wager that the three effective drugs should ignite some action in D2 SPNs, and might do nothing at D1.